New hope for rare dementia: experimental drug DNL593 enters human trials
NCT ID NCT05262023
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 40 times
Summary
This study tests an experimental drug called DNL593 in healthy volunteers and people with frontotemporal dementia (FTD), a rare brain disease that causes personality changes and memory loss. The trial aims to check if the drug is safe, how the body processes it, and whether it might help. It includes a small number of participants and an optional long-term follow-up.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRONTOTEMPORAL DEMENTIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ASST degli Spedali Civili di Brescia
Brescia, Italy
-
Azienda Ospedaliera Cardinale G Panico
Tricase, Italy
-
Azienda Ospedaliera Universitaria Careggi
Florence, Italy
-
CHU Rouen
Rouen, France
-
CHU Toulouse
Toulouse, France
-
CHU de Nantes
Nantes, France
-
Campus Neurológico Sénior
Torres Vedras, Portugal
-
Erasmus University Medical Center
Rotterdam, Netherlands
-
Faculdade de Medicina Da Universidade de São Paulo
São Paulo, Brazil
-
Fakultni nemocnice v Motole
Prague, Czechia
-
Grupo de Neurosicencias de la Universidad de Antioquia
Medellín, Colombia
-
Hospital Clinic de Barcelona
Barcelona, Barcelona, 8036, Spain
-
Hospital Universitario San Ignacio
Bogotá, Colombia
-
Hospital Universitario Virgen del Rocio
Seville, Sevilla, 41013, Spain
-
Hospital Universitario de Donostia
Donostia / San Sebastian, Guipúzcoa, 20014, Spain
-
Hospital de Braga
Braga, Portugal
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
IRCCS Istituto Auxologico Italiano
Milan, Italy
-
Istanbul University Istanbul Medical Faculty
Istanbul, Turkey (Türkiye)
-
John Hopkins University
Baltimore, Maryland, 21218, United States
-
L2IP - Instituto de Pesquisas Clinicas LTDA
Brasília, Brazil
-
Ondokuz Mayis University Hospital
Samsun, Turkey (Türkiye)
-
Simbec Orion
Merthyr Tydfil, Wales, CF48 4DR, United Kingdom
-
UZ Leuven
Leuven, Belgium
-
University of Antwerp
Antwerp, Belgium
-
University of California San Francisco
San Francisco, California, 94143, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DNL593
What this could lead to
If successful, this could point toward a treatment that slows or manages frontotemporal dementia, a currently untreatable disease.
What could go wrong
This is an early-phase trial with only 85 participants, so results may not confirm effectiveness. The drug may cause side effects or fail to show benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.